CDK4 and neoplasm: Although the three approved CDK4/6 inhibitors—palbociclib, ribociclib, and abemaciclib—seem to have essentially overlapping patterns of activity, as multikinase inhibitors, they could have many other mechanisms of action on several cellular populations other than tumor cells, particularly in the bone microenvironment.